Daxor (DXR) EPS (Basic) : $0.14 (TTM As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Daxor EPS (Basic)?

Daxor's basic earnings per share (Basic EPS) for the six months ended in Dec. 2023 was $1.55. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.14.

Daxor's EPS (Diluted) for the six months ended in Dec. 2023 was $0.69. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.72.

Daxor's EPS without NRI for the six months ended in Dec. 2023 was $0.69. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.72.

During the past 12 months, Daxor's average EPS without NRIGrowth Rate was -83.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Daxor's highest 3-Year average EPS without NRI Growth Rate was 128.50% per year. The lowest was -166.80% per year. And the median was -8.20% per year.

Daxor EPS (Basic) Historical Data

The historical data trend for Daxor's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daxor EPS (Basic) Chart

Daxor Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.08

-0.28

1.17

0.87

0.14

Daxor Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															1.55	-0.46	1.33	-1.41	1.55

Daxor EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Daxor's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(0.281	-	0)	/	4.631
	=	0.06

Daxor's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(3.318	-	0)	/	4.799
	=	0.69

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.14

Daxor (NAS:DXR) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Daxor EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Daxor's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Daxor (DXR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Daxor Corp (NAS:DXR) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

DX5:Germany

Address

109 Meco Lane, Oak Ridge, TN, USA, 37830

Website

https://www.daxor.com

Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. It develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.

Executives

Robert J Michel	officer: CHIEF FINANCIAL OFFICER	C/O ASTA FUNDING, INC., 210 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Michael Richard Feldschuh	director	71 GRAND STREET #2, NEW YORK NY 10013
Joy S. Goudie	director	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Caleb Desrosiers	director	DAXOR CORPORATION, 109 MECO LANE, OAK RIDGE TN 37830
Henry D. Cremisi	director	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Edward Feuer	director	2 WALL STREET, 10TH FLOOR, NEW YORK NY 10005
Soren Thompson	officer: V.P./BUSINESS DEVELOPMENT	180 CENTRAL PARK SOUTH, APT. 805, NEW YORK NY 10019
Jonathan Adam Feldschuh	director, officer: CHIEF SCIENTIFIC OFFICER	DAXOR CORPORATION, 350 5TH AVENUE, SUITE 4740, NEW YORK NY 10118
Joseph Feldschuh	officer: President	615 W. 252ND STREET, BRONX NY 10471
Estate Of Joseph Feldschuh	other: FOUNDER	350 FIFTH AVENUE, SUITE 4740, NEW YORK NY 10118
Diane Marie Meegan	officer: Corporate Secretary	259 NEW YORK AVENUE, JERSEY CITY NJ 07307
Bernhard Saxe	director	6805 WILD ROSE COURT, SPRINGFIELD VA 25152
Robert Willens	director	200 EAST 74TH ST APT 18C, NEW YORK NY 10021
Philip Nordan Hudson	director	P.O. BOX 160892, SAN ANTONIO TX 78280-3092
Everis Engstrom	officer: Vice President	3244 BLACK FOX ROAD, WASHBURN TN 37888